Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia
Christoph Kornauth(Munich Leukemia Laboratory (Germany)), Philipp B. Staber(Vienna General Hospital)
Cited by 9
Related Papers
Sustained PU.1 Levels Balance Cell-Cycle Regulators to Prevent Exhaustion of Adult Hematopoietic Stem Cells
|Molecular Cell|2013|163
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia
|Blood|2019|161
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia
|Blood|2021|37
Inhibitory NKG2A+ and absent activating NKG2C+ NK cell responses are associated with the development of EBV+ lymphomas
|Frontiers in Immunology|2023|16